Addex Therapeutics Ltd (ADXN)
8.79
-0.21
(-2.33%)
USD |
NASDAQ |
May 16, 16:00
8.77
-0.02
(-0.23%)
After-Hours: 20:00
Addex Therapeutics Enterprise Value: 4.792M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 4.792M |
| May 15, 2024 | 5.016M |
| May 14, 2024 | 5.497M |
| May 13, 2024 | 5.369M |
| May 10, 2024 | 5.380M |
| May 09, 2024 | 4.963M |
| May 08, 2024 | 5.016M |
| May 07, 2024 | 5.176M |
| May 06, 2024 | 5.176M |
| May 03, 2024 | 4.963M |
| May 02, 2024 | 4.856M |
| May 01, 2024 | 4.065M |
| April 30, 2024 | 3.573M |
| April 29, 2024 | 3.456M |
| April 26, 2024 | 12.60M |
| April 25, 2024 | 11.87M |
| April 24, 2024 | 12.02M |
| April 23, 2024 | 15.43M |
| April 22, 2024 | 16.00M |
| April 19, 2024 | 16.83M |
| April 18, 2024 | 17.80M |
| April 17, 2024 | 18.91M |
| April 16, 2024 | 19.55M |
| April 15, 2024 | 21.85M |
| April 12, 2024 | 22.73M |
| Date | Value |
|---|---|
| April 11, 2024 | 23.35M |
| April 10, 2024 | 24.51M |
| April 09, 2024 | 25.22M |
| April 08, 2024 | 18.75M |
| April 05, 2024 | 14.50M |
| April 04, 2024 | 12.90M |
| April 03, 2024 | 11.86M |
| April 02, 2024 | 9.548M |
| April 01, 2024 | 9.291M |
| March 28, 2024 | 9.078M |
| March 27, 2024 | 8.597M |
| March 26, 2024 | 8.276M |
| March 25, 2024 | 8.003M |
| March 22, 2024 | 7.923M |
| March 21, 2024 | 8.329M |
| March 20, 2024 | 8.436M |
| March 19, 2024 | 8.260M |
| March 18, 2024 | 8.201M |
| March 15, 2024 | 7.913M |
| March 14, 2024 | 7.378M |
| March 13, 2024 | 7.207M |
| March 12, 2024 | 7.902M |
| March 11, 2024 | 7.966M |
| March 08, 2024 | 7.688M |
| March 07, 2024 | 5.486M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-9.505M
Minimum
Jun 28 2022
87.48M
Maximum
Dec 24 2020
15.07M
Average
9.341M
Median
Mar 03 2022
Enterprise Value Benchmarks
| AC Immune SA | 221.07M |
| CRISPR Therapeutics AG | 2.619B |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -95.36M |
| MoonLake Immunotherapeutics | 2.032B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.224M |
| Revenue (Quarterly) | 0.1731M |
| Total Expenses (Quarterly) | 3.200M |
| EPS Diluted (Quarterly) | -4.062 |
| Profit Margin (Quarterly) | -1.86K% |
| Earnings Yield | -212.3% |
| Normalized Earnings Yield | -206.10 |